How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,088 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

381. Misoprostol for Reduction of Blood Loss During Fibroid Surgery

-operative hemoglobin >8 g/dl Willing to have buccal administration of misoprostol or a placebo at least one hour pre-procedure. Ability to understand and the willingness to sign a written informed consent. Admissible medical/surgical history Can be previously treated with Depo-Lupron, Depo-Provera, or Oral Contraceptive pills Intraoperative use of vasopressin and uterine tourniquet is permissible Can have had prior Cesarean delivery Exclusion Criteria: Patients who have had a prior abdominal myomectomy

2014 Clinical Trials

382. A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy

of amenorrhea, or surgically sterile, 2) Confirming the patient is using one of the following methods of birth control for a minimum of one month prior to entry into this study: Intrauterine device (IUD), oral contraceptives, Depo-Provera, or Norplant, 3) Confirming a negative urine dipstick test taken the morning of receiving the investigational agent [18F]fluciclatide. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2014 Clinical Trials

383. Relative Bioavailability of Tipranavir (TPV)/Ritonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy Volunteers

a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and 60 days after completion/termination of the trial Are breast-feeding Use any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to Day 0 and for the duration of the study. Due to long half-life, subjects using Depo-Provera® within 6 months prior to Day 1 are excluded from participation in this study Use of hormone

2014 Clinical Trials

384. Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and 60 days after completion/termination of the trial Are breast-feeding. Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to Day 1 and for the duration of the study. Due to long half-life, subjects using Depo-Provera® within six months prior to Day 1 will be excluded from participation in this study Use of hormone replacement therapy

2014 Clinical Trials

385. Naproxen Sodium/ASA Platelet Study

., oral or patch contraceptives, intrauterine device, Depo-Provera®, or a double barrier and have a negative pregnancy test at Screening and immediately prior to investigational product administration on Day 1 and Day 6. Female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy Results of screening and clinical laboratory tests are within normal range or considered not clinically significant by the Principal Investigator

2014 Clinical Trials

386. Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

of 0 or 1 including patients who are not surgical candidates due to comorbid conditions. Peripheral neuropathy: must be < grade 1 Women of childbearing potential must have a negative pregnancy test. All patients of childbearing potential must be willing to consent to using effective contraception, i.e., intrauterine device (IUD), Birth control pills, Depo-Provera, and condoms while on treatment and for 3 months after their participation in the study ends. No experimental intravesical therapy within

2014 Clinical Trials

387. Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir

and 60 days after completion/termination of the trial Are breast-feeding Participation in another trial with an investigational medicine within 2 months prior to Day 0 of this study Use of any medication listed in the protocol within 30 days prior to Day 0 of this study Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to Day 0 and for the duration of the study. Due to long half-life,subjects using of Depo-Provera within six months

2014 Clinical Trials

388. An Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication Miconazole Nitrate on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring in Normal Ovulating Women

drug within the last 30 days (prior to screening) BMI >29 Use of liver enzyme inducers on a regular basis Use of monthly injectable contraceptives, unless suspended 2 months before initiation of the treatment. Use of Depo-Provera [depo-medroxyprogesterone (DMPA)] unless suspended 6 months before treatment Current use of implanted hormonal contraceptives, including Mirena [progestin containing intrauterine system (IUS)], Jadelle, Norplant, Implanon or Nexplanon (if now available in the USA).** Known

2014 Clinical Trials

389. Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome-Constipation (IBS-C)

. Positive pregnancy test in women of child-bearing potential. Pregnant or breast-feeding or planning on becoming pregnant. Women of child-bearing potential not using effective contraception. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Intrauterine devices Vasectomy of partner (shown

2014 Clinical Trials

390. Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris

gonadotropin [hCG], begin treatment during a normal menstrual period and must agree to use a medically accepted method of contraception during the study. The following are considered acceptable methods of birth control for the purpose of this study: oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double barrier methods (e.g., condom and spermicide), contraceptive injection (Depo-Provera®), intrauterine device (IUD), hormonal IUD (Mirena®), and abstinence

2014 Clinical Trials

391. Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis

of birth control for the purpose of this study: oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double barrier methods (e.g., condom and spermicide), contraceptive injection (Depo-Provera®), intrauterine device (IUD), hormonal IUD (Mirena®), and abstinence with a documented second acceptable method of birth control if the subject becomes sexually active. Subjects entering the study who are on hormonal contraceptives must have been on the method for at least 90

2014 Clinical Trials

392. Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars

is mandibular and fully or partially impacted by bone). Supernumerary or affected adjacent teeth may be removed at the surgeon's discretion. Subject has body mass index of 18.0 to 30.0 kg/m2, inclusive. Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device (copper/hormonal), NuvaRing®, Depo-Provera®, or double-barrier method

2014 Clinical Trials

393. Comparison of Two Formulations of Proellex for Oral Administration

. (ALT or AST exceeding 2.0 x ULN AND total bilirubin exceeding 1.5 x ULN at screening and confirmed on repeat). Received an investigational drug in the 30 days prior to the screening for this study Women with a history of PCOS Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to screening and during the study. Use of oral contraceptives in the preceding 2 weeks. Use of Depo-Provera® in the preceding 10 months

2014 Clinical Trials

394. Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

Criteria: Healthy adults (male or non-pregnant, non-lactating female) 18 to 50 years of age (inclusive) at the time of screening If the subject is female, Non-childbearing potential (ie, either surgically sterilized or one year post-menopausal), abstinent or using adequate contraceptive precautions (eg, intrauterine contraceptive device; oral contraceptives; diaphragm or condom in combination with contraceptive jelly, cream or foam; Norplant® or Depo-Provera®) during this study and must agree

2014 Clinical Trials

395. Butrans for Treatment of Restless Legs Syndrome

accepted method of birth control. Acceptable forms of birth control include: Condom + spermicide Diaphragm + spermicide Oral contraceptive pills, hormone implants (like Norplant), or injections(like Depo-Provera) Intrauterine Device Exclusion Criteria: Lifetime history of DSM-IVopiod, alcohol, or other substance abuse. History of opioid treatment for RLS with inadequate response Positive urine toxicology screen at visit 1. Another chronic pain syndrome that would, in the opinion of the investigator

2014 Clinical Trials

396. A Quit Smoking Study Using Smartphones

method of birth control during a 2 month period (1 month of nicotine patch and 1 month after). (Acceptable methods of birth control include: abstinence, condoms, diaphragm, birth control pills or injectable contraceptive [e.g., Depo-Provera], an intrauterine device, hysterectomy, tubal ligation, sterilization, vasectomy, or being more than 2 years post-menopausal.) Participants need to report playing video games for no more than 60 minutes a day. Although participants can play console games

2014 Clinical Trials

397. Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects

A known or suspected hypersensitivity to any of the trial medications or their excipients or any other NSAIDs (Non-Steroid Anti-Inflammatory Drug) A history of gastrointestinal ulcer, perforation or bleeding A history of cerebrovascular bleeding or any other bleeding disorder Women of childbearing potential not using adequate contraception (e.g, intrauterine device, contraceptive pills, Depo-Provera® implant, barrier device) for at least 3 months prior to, and for the duration of trial participation

2014 Clinical Trials

398. Molecular-Guided Therapy for Childhood Cancer

is required for female participants of child bearing potential (≥13 years of age or after onset of menses) Both male and female post-pubertal study subjects need to agree to use one of the more effective birth control methods during treatment and for six months after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one

2014 Clinical Trials

399. Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

per day or 20 mg every other day Patients who are being treated with monamine oxidase inhibitors or tricyclic antidepressants Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e. oral or injectable eg Depo-Provera or Noristerat contraceptives, intrauterine devices, diaphragm plus spermicide or subdermal implants eg: Norplant®) Patients with, in the opinion of the investigator, a history of and/or active significant alcohol or drug

2014 Clinical Trials

400. Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease

of prednisolone per day or 20 mg every other day Patients who are being treated with monamine oxidase inhibitors or tricyclic antidepressants Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e. oral or injectable eg Depo-Provera or Noristerat contraceptives, intrauterine devices, diaphragm (plus spermicide) or subdermal implants eg: Norplant®) Patients with, in the opinion of the investigator, a history of and/or active significant alcohol

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>